MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Total Assets 2011-2026 | CALT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.46 B | 1.51 B | 845 M | 648 M | 62.3 M | 27.3 M | 28.1 M | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.51 B | 27.3 M | 654 M |
Quarterly Total Assets Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.46 B | 1.34 B | 1.46 B | - | 1.19 B | 1.34 B | 1.46 B | - | 1.49 B | - | 845 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.49 B | 845 M | 1.32 B |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
76.8 M | $ 4.68 | 9.09 % | $ 65.8 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.54 | -1.17 % | $ 1.31 B |  Canada |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Organogenesis Holdings
ORGO
|
599 M | $ 2.37 | -6.32 % | $ 300 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 23.15 | -2.07 % | $ 1.07 B | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.75 | 0.35 % | $ 2.1 B | Canada |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.11 | -1.77 % | $ 119 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 1.2 | 1.69 % | $ 1.49 M | USA |
 |
Harrow Health
HROW
|
399 M | $ 38.23 | -2.1 % | $ 1.41 B | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 7.27 | 2.83 % | $ 636 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.41 | -0.58 % | $ 86.3 M | Canada |
 |
Tilray
TLRY
|
4.31 B | $ 5.56 | -1.77 % | $ 3.44 B | Canada |
 |
Jupiter Wellness
JUPW
|
41 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.36 | -1.45 % | $ 130 M | Canada |
 |
Evolus
EOLS
|
226 M | $ 6.36 | -0.47 % | $ 410 M | USA |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.44 | -1.03 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
60.4 M | $ 2.24 | -1.75 % | $ 302 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 9.5 | 4.05 % | $ 486 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
10.6 M | $ 0.84 | -3.45 % | $ 3.62 M | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
267 M | $ 22.5 | 0.58 % | $ 144 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 7.32 | -1.48 % | $ 289 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.92 | -4.35 % | $ 45.9 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
37.2 B | $ 17.17 | -1.27 % | $ 20 B | USA |
 |
Zomedica Corp.
ZOM
|
127 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
57.1 M | $ 0.83 | 6.76 % | $ 29.9 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
31 M | $ 0.53 | 1.26 % | $ 2.27 M |  China |
 |
TherapeuticsMD
TXMD
|
37.7 M | $ 1.98 | -1.49 % | $ 22.9 M | USA |